Email updates

Keep up to date with the latest news and content from Retrovirology and BioMed Central.

This article is part of the supplement: AIDS Vaccine 2012

Open Access Open Badges Poster presentation

Genetic variability and drug resistance mutations in HIV-1 infected individuals on HAART or drug naïve in Limbe, Cameroon

L Agyingi1*, D Barengolts1, L Mayr1, T Kinge2, M MBida3 and P Nyambi1

  • * Corresponding author: L Agyingi

Author Affiliations

1 New York University School of Medicine, New York, NY, USA

2 Limbe Regional Hospital, South West Region, Limbe, Cameroon

3 Faculty of Biomedical Sciences, University of Dschang, Dschang, Cameroon

For all author emails, please log on.

Retrovirology 2012, 9(Suppl 2):P158  doi:10.1186/1742-4690-9-S2-P158

The electronic version of this article is the complete one and can be found online at:

Published:13 September 2012

© 2012 Agyingi et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Cameroon is a country in West Central Africa with a population of about 20 million inhabitants, with an estimated HIV prevalence of 5.1% in the general population. The HIV epidemic in this region is marked by a broad genetic diversity dominated by Circulating Recombinant Forms (CRFs).


To characterize HIV-1 genotypes circulating in HIV positive individuals in Limbe, Cameroon, we phylogenetically analyzed blood samples from 116 HIV positive patients. Of 116 samples tested, 110 were amplified by nested PCR at the Gag, Pol and Env genes. Sequences obtained were phylogenetically analyzed with reference sequences from the Los Alamos database. The RT region of samples was also amplified to identify mutations that conferred resistance to Reverse Transcriptase inhibitors (RTIs) using the Stanford University Drug resistance database.


Our results revealed a broad genetic diversity, dominated by circulating recombinant forms as follows: CRF02_AG 50.4% (n=54), CRF22_01A1 7.4% (n=8) F2 3.7% (n=4), D 2% (n=2), CRF43_02G 2.8% (n=3), CRF18_CPX 2.8% (n=3) and recombinant forms (RFs) 31.7 %( n=34). Most RFs contained CRF02_AG in one or two HIV loci analyzed. RT sequences of 3 patients on HAART and 15 drug naïve individuals harbored mutations which conferred resistance to RTIs.


CRF02_AG continues to be the most predominant strain in Cameroon, CRF22_01A1 on the increase. Identification of drug resistance strains in drug naïve patients suggest these viruses are being transmitted in the study population and highlights the need of drug resistance testing before start of ART for HIV patients.